May 28, 2025
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
Apr 29, 2025
Insmed To Present at the BofA Securities 2025 Health Care Conference
Mar 25, 2025
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Feb 24, 2025
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
Feb 10, 2025
Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025
Feb 07, 2025
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 03, 2025
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 02, 2025
Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 02, 2024
Insmed To Present at December 2024 Investor Conferences
Nov 06, 2024
Insmed To Present at November 2024 Investor Conferences
Oct 31, 2024
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
Oct 23, 2024
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
Oct 17, 2024
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
Oct 04, 2024
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 02, 2024
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 05, 2024
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 03, 2024
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
May 30, 2024
Insmed to Host Commercial Webinar on June 4, 2024
May 30, 2024
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
May 27, 2024
Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis